Careteq (ASX:CTQ) Cash Conversion Cycle: 3,145.44 (As of Dec. 2025)


What is Careteq Cash Conversion Cycle?

Careteq ASX:CTQ Cash Conversion Cycle is 3,145.44 as of Dec. 2025. The stock has 8 warning signs investors should review.

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Careteq's Days Sales Outstanding for the six months ended in Dec. 2025 was 3145.44.
Careteq's Days Inventory for the six months ended in Dec. 2025 was 0.
Careteq's Days Payable for the six months ended in Dec. 2025 was 0.
Therefore, Careteq's Cash Conversion Cycle (CCC) for the six months ended in Dec. 2025 was 3,145.44.


Careteq  (ASX:CTQ) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Careteq Cash Conversion Cycle Related Terms


Careteq Cash Conversion Cycle Historical Data

* Premium members only.

The historical data trend for Careteq's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Careteq Cash Conversion Cycle Chart

Careteq Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Cash Conversion Cycle
0.00 -1,243.02 -321.66 23.19 15.73

Careteq Semi-Annual Data
Jun21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only -447.90 74.64 39.00 32.97 3,145.44

ASX:CTQ vs VEEV, BTSG, TEM: Cash Conversion Cycle Comparison

For the Health Information Services subindustry, Careteq's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Careteq Cash Conversion Cycle vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Careteq's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Careteq's Cash Conversion Cycle falls into.



Careteq Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Careteq's Cash Conversion Cycle for the fiscal year that ended in Jun. 2025 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=15.73+0-0
=15.73

Careteq's Cash Conversion Cycle for the quarter that ended in Dec. 2025 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=3145.44+0-0
=3,145.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash Conversion Cycle →
What does a Cash Conversion Cycle of 3,145.44 mean?
Careteq (ASX:CTQ) has a Cash Conversion Cycle of 3,145.44 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Careteq and its competitors.
Is Careteq's Cash Conversion Cycle too high?
Careteq's current Cash Conversion Cycle is 3,145.44. The Healthcare Providers & Services industry median Cash Conversion Cycle is 18.10. Careteq's value of 3,145.44 is 17278.1% above this industry median.
How does Careteq's Cash Conversion Cycle compare to VEEV and BTSG?
Careteq's Cash Conversion Cycle of 3,145.44 can be compared against companies in the Healthcare Providers & Services industry. The industry median Cash Conversion Cycle is 18.10. Careteq's value of 3,145.44 is 17278.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Healthcare Providers & Services company?
The median Cash Conversion Cycle among Healthcare Providers & Services companies is 18.10, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Careteq's current Cash Conversion Cycle of 3,145.44 is 17278.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Careteq and its competitors. For the Healthcare Providers & Services industry, the median Cash Conversion Cycle is 18.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Careteq's current Cash Conversion Cycle is 3,145.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Careteq stock overvalued right now?
Based on GuruFocus' analysis, Careteq (ASX:CTQ) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.01, compared to a current price of A$0.01 — trading 20% above its estimated fair value. The current Cash Conversion Cycle is 3,145.44 and 17278.1% above the Healthcare Providers & Services industry median of 18.10. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Careteq (ASX:CTQ), the current Cash Conversion Cycle is 3,145.44 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Careteq Business Description

Address 99 Queen Street, Level 10, Melbourne, VIC, AUS, 3000
Careteq Ltd provides Residential Medication Management Review and Home Medicines Review services as part of the Medication Management Programs, generating revenue from medication review, education, and support services. The company focuses on medication management and home care solutions to provide continuity of care and improve clinical outcomes for patients through Home Medication Reviews. Medication-related harm includes adverse drug reactions, medication errors, and complications that jeopardise patient safety and increase healthcare costs. The company operates in Australia.